Next Article in Journal
Flavin-Dependent Enzymes in Cancer Prevention
Next Article in Special Issue
Expression of Partitioning Defective 3 (Par-3) for Predicting Extrahepatic Metastasis and Survival with Hepatocellular Carcinoma
Previous Article in Journal
UVA Irradiation of Dysplastic Keratinocytes: Oxidative Damage versus Antioxidant Defense
Previous Article in Special Issue
The Role of Sox Genes in Lung Morphogenesis and Cancer
Article Menu

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2012, 13(12), 16737-16750; doi:10.3390/ijms131216737

Inhibitor of Apoptosis Protein-Like Protein-2 as a Novel Serological Biomarker for Breast Cancer

1
Department of Biochemistry & Molecular Biology, College of Medical Science, Jishou University, Jishou 416000, China
2
Department of Biochemistry & Molecular Biology, Gannan Medical University, Ganzhou 341000, China
3
Hunan Provincial Key Laboratory for Biology and Control of Plant Diseases and Insect Pests, College of Bio-Safety Science & Technology, Hunan Agricultural University, Changsha 410128, China
4
Institute of Medical Biology, Chinese Academy of Medical Sciences, Kunming 650118, China
5
Clinical Laboratory, the First Affiliated Hospital, Gannan Medical University, Ganzhou 341000, China
These authors contributed equally to this work.
*
Authors to whom correspondence should be addressed.
Received: 28 September 2012 / Revised: 22 November 2012 / Accepted: 30 November 2012 / Published: 7 December 2012
(This article belongs to the Special Issue Advances in Cancer Diagnosis)
View Full-Text   |   Download PDF [510 KB, uploaded 19 June 2014]   |  

Abstract

Inhibitor of apoptosis protein-like protein-2 (ILP-2) has only been detected in the testis and in lymphoblastoid cells. Although previous studies have not reported the presence of ILP-2 in breast cancer tissues, this study indicates the presence of ILP-2 in breast cancer serum samples. To validate whether ILP-2 is a novel serological biomarker for breast cancer, we conducted two-dimensional gel electrophoresis (2DE) and matrix-assisted laser desorption/ionization-time of flight mass spectrometry analysis on 400 breast cancer serum samples and 40 non-cancer serum samples (i.e., healthy controls). We then performed a Western blot analysis of 10 breast cancer serum samples and 10 non-cancer serum samples. Finally, we analyzed 35 serum samples from healthy controls or subjects with breast cancer, other types of cancer, galactophore hyperplasia or breast cancer post-surgery by using 2DE and enzyme-linked immunosorbent assay. Our results indicate that ILP-2 is a novel breast cancer biomarker in the peripheral blood.
Keywords: ILP-2; breast cancer; serological biomarker ILP-2; breast cancer; serological biomarker
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Xiang, M.; Zhou, W.; Gao, D.; Fang, X.; Liu, Q. Inhibitor of Apoptosis Protein-Like Protein-2 as a Novel Serological Biomarker for Breast Cancer. Int. J. Mol. Sci. 2012, 13, 16737-16750.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top